Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,135.95
(
-0.04%
)
US TECH 100
26,674.80
(
1.42%
)
Dow Jones
48,861.81
(
-0.57%
)
Brent Oil
113.14
(
0.68%
)
Bitcoin
75,513.84
(
-0.35%
)
News Focus
News Focus
Post# of 257470
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

AlpineBV_Miller

Send PM Follow Ignore
Followers 54
Posts 1150
Boards Moderated 0
Alias Born 11/12/2005

AlpineBV_Miller

Re: DewDiligence post# 31127

Monday, 07/10/2006 11:04:26 PM

Monday, July 10, 2006 11:04:26 PM

Post# of 257470
If you know your BLA is rate-limited by a CMC section that won't be ready until Q4, why bother rushing the clinical section? What strategic or other value do you get by submitting the clinical section early given the FDA is already overwhelmed with filings?


Unless otherwise indicated, this is the personal viewpoint of David Miller and not necessarily that of Biotech Stock Research, LLC

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today